CLINICAL TRIALS PROFILE FOR APREPITANT
✉ Email this page to a colleague
505(b)(2) Clinical Trials for APREPITANT
| Trial Type | Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|---|
| New Indication | NCT00090155 ↗ | 2 Doses of an Approved Drug Being Studied for a New Indication for the Prevention of Postoperative Nausea and Vomiting (0869-090)(COMPLETED) | Completed | Merck Sharp & Dohme Corp. | Phase 3 | 2003-09-26 | The purpose of this study is to assess the safety and efficacy of 2 doses of an approved drug for a new indication in the prevention of postoperative nausea and vomiting in patients receiving general anesthesia for open abdominal surgery requiring overnight hospital stay. |
| New Indication | NCT00090246 ↗ | 2 Doses of an Approved Drug Being Studied for a New Indication for the Prevention of Postoperative Nausea and Vomiting (0869-091) | Completed | Merck Sharp & Dohme Corp. | Phase 3 | 2004-05-13 | The purpose of this study is to assess the safety and efficacy of 2 doses of an approved drug for a new indication in the prevention of postoperative nausea and vomiting in patients receiving general anesthesia for open abdominal surgery requiring overnight hospital stay. |
| New Combination | NCT01012336 ↗ | Safety and Efficacy of Aprepitant, Ramosetron, and Dexamethasone for Chemotherapy-Induced Nausea and Vomiting in Patients With Ovarian Cancer Treated With Taxane/Carboplatin | Completed | Merck Sharp & Dohme Corp. | Phase 2 | 2010-05-01 | The current recommended guideline for patients receiving moderately emetogenic chemotherapy (MEC) is the combination of a 5-HT3 receptor antagonist and corticosteroid. Incidence of chemotherapy induced nausea and vomiting (CINV) is approximately 50% in patients receiving MEC. An incidence rate of 25-38% for delayed emesis and 55-60% for delayed nausea has been observed. Hence, there is clearly a need for more effective prevention of CINV in patients receiving MEC, especially in women with ovarian carcinoma who are particularly susceptible to these symptoms. Therefore the investigators designed a study with the objective to evaluate if new combination (Aprepitant/Ramosetron/Dexamethasone) may improve actual CINV control in ovarian carcinoma patients treated with taxane/carboplatin. |
| New Combination | NCT01012336 ↗ | Safety and Efficacy of Aprepitant, Ramosetron, and Dexamethasone for Chemotherapy-Induced Nausea and Vomiting in Patients With Ovarian Cancer Treated With Taxane/Carboplatin | Completed | Samsung Medical Center | Phase 2 | 2010-05-01 | The current recommended guideline for patients receiving moderately emetogenic chemotherapy (MEC) is the combination of a 5-HT3 receptor antagonist and corticosteroid. Incidence of chemotherapy induced nausea and vomiting (CINV) is approximately 50% in patients receiving MEC. An incidence rate of 25-38% for delayed emesis and 55-60% for delayed nausea has been observed. Hence, there is clearly a need for more effective prevention of CINV in patients receiving MEC, especially in women with ovarian carcinoma who are particularly susceptible to these symptoms. Therefore the investigators designed a study with the objective to evaluate if new combination (Aprepitant/Ramosetron/Dexamethasone) may improve actual CINV control in ovarian carcinoma patients treated with taxane/carboplatin. |
| >Trial Type | >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
All Clinical Trials for APREPITANT
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00034983 ↗ | Treatment of Patients With Major Depressive Disorder With MK0869 (0869-066)(COMPLETED) | Completed | Merck Sharp & Dohme Corp. | Phase 3 | 2001-10-29 | A clinical study to determine the efficacy and safety of an investigational medication (MK0869) in the treatment of depression |
| NCT00035048 ↗ | Treatment of Patients With Major Depressive Disorder With MK0869 (0869-068)(COMPLETED) | Completed | Merck Sharp & Dohme Corp. | Phase 3 | 2001-11-21 | A clinical study to determine the efficacy and safety of an investigational medication (MK0869) in the treatment of depression. |
| NCT00035282 ↗ | Treatment of Patients With Major Depressive Disorder With MK0869 (0869-060)(COMPLETED) | Completed | Merck Sharp & Dohme Corp. | Phase 3 | 2001-09-01 | A clinical study to determine the efficacy and safety of an investigational medication (MK0869) in the treatment of depression. |
| NCT00048594 ↗ | Long Term Treatment of Patients With Major Depressive Disorder With MK0869 (0869-065)(COMPLETED) | Completed | Merck Sharp & Dohme Corp. | Phase 3 | 2002-01-03 | A clinical study to determine the efficacy and safety of an investigational medication (MK0869) in the treatment of depression. |
| NCT00048607 ↗ | Treatment of Patients With Major Depressive Disorder With MK0869 (0869-062)(COMPLETED) | Completed | Merck Sharp & Dohme Corp. | Phase 3 | 2002-07-30 | A clinical study to determine the efficacy and safety of MK0869 in the treatment of depression |
| NCT00080444 ↗ | Study of Aprepitant (MK-0869) for Chemotherapy-Induced Nausea and Vomiting (CINV) in Adolescent Participants (MK-0869-097) | Completed | Merck Sharp & Dohme Corp. | Phase 3 | 2004-04-01 | This study is being conducted to demonstrate that aprepitant (MK-0869) prevents nausea and vomiting caused by emetogenic cancer chemotherapy in adolescent participants. Participants treated with emetogenic cancer chemotherapies that include either cisplatin, cyclophosphamide, or carboplatin, or participants who experienced nausea and/or vomiting when treated with a previously administered chemotherapy regimen that is planned to be repeated will be enrolled in this study. In the double-blind Part 1 of this study, enrolled participants will be randomized to receive either aprepitant or standard therapy. In Part 2 of this study, enrolled participants will receive open-label aprepitant. |
| NCT00090155 ↗ | 2 Doses of an Approved Drug Being Studied for a New Indication for the Prevention of Postoperative Nausea and Vomiting (0869-090)(COMPLETED) | Completed | Merck Sharp & Dohme Corp. | Phase 3 | 2003-09-26 | The purpose of this study is to assess the safety and efficacy of 2 doses of an approved drug for a new indication in the prevention of postoperative nausea and vomiting in patients receiving general anesthesia for open abdominal surgery requiring overnight hospital stay. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for APREPITANT
Condition Name
Clinical Trial Locations for APREPITANT
Trials by Country
Clinical Trial Progress for APREPITANT
Clinical Trial Phase
Clinical Trial Sponsors for APREPITANT
Sponsor Name
